USAQ
QHSLab, Inc.
0.00 (0.00%)0.40USD0成交股數6.0M市值13.3本益比(近四季)2.0股價營收比+40.0%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 847K+40% | 729K+13% | 704K+29% | 737K+56% | 605K+24% | 645K+105% | 544K+62% | 473K+17% | 489K | 315K | 336K | 405K |
| 營業成本 | 258K | 258K | 216K | 243K | 206K | 215K | 179K | 179K | 202K | 125K | 147K | 178K |
| 毛利 | 590K+48% | 471K+10% | 488K+34% | 494K+68% | 399K+39% | 430K+126% | 365K+93% | 294K+30% | 286K | 190K | 190K | 227K |
| 毛利率 | 69.6% | 64.6% | 69.4% | 67.0% | 65.9% | 66.6% | 67.1% | 62.2% | 58.6% | 60.3% | 56.3% | 56.0% |
| 研發費用 | 115K | 121K | 116K | 133K | 112K | 124K | 80K | 65K | 43K | 45K | 45K | 61K |
| 銷售管理費用 | 255K | 208K | 70K | 64K | 150K | 156K | 56K | 47K | 90K | 53K | 47K | 56K |
| 營業利益 | 45K+293% | −94K+684% | 36K-60% | 96K+221% | 12K-15% | −12K-75% | 89K-353% | 30K-184% | 14K | −48K | −35K | −36K |
| 營業利益率 | 5.3% | -13.0% | 5.0% | 13.1% | 1.9% | -1.9% | 16.4% | 6.3% | 2.8% | -15.4% | -10.5% | -8.8% |
| 稅後淨利 | 38K-172% | −104K+31% | −358K-820% | 33K-1256% | −53K+186% | −80K-8% | 50K-160% | −3K-97% | −19K | −87K | −82K | −107K |
| 淨利率 | 4.5% | -14.3% | -50.9% | 4.5% | -8.7% | -12.3% | 9.1% | -0.6% | -3.8% | -27.5% | -24.5% | -26.4% |
| 稀釋 EPS | 0.00 | 0.00-100% | 0.03 | 0.00 | 0.00 | -0.010% | 0.00-100% | 0.00-100% | 0.00 | -0.01 | -0.01 | -0.01 |
| 稀釋股數 | 23.1M | 15.0M | 19.3M | 19.3M | 11.3M | 11.2M | 18.5M | 10.2M | 9.9M | 9.4M | 9.3M | 9.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 317K | 362K | 636K | 158K | 168K | 61K | 96K | 104K | 67K | 52K | 50K | 109K |
| 應收帳款 | 343K | 201K | 191K | 210K | 148K | 195K | 198K | 132K | 131K | 71K | 84K | 102K |
| 存貨 | 9K | 28K | 36K | 27K | 42K | 29K | 40K | 6K | 37K | 25K | 39K | 35K |
| 總資產 | 1.9M | 1.9M | 2.2M | 1.7M | 1.7M | 1.7M | 1.8M | 1.7M | 1.7M | 1.7M | 1.7M | 1.8M |
| 有息負債 | – | 37K | 91K | – | – | – | – | – | – | – | – | – |
| 總負債 | 376K | 368K | 546K | 2.3M | 2.4M | 2.3M | 2.1M | 2.1M | 2.1M | 2.1M | 2.0M | 2.1M |
| 股東權益 | 1.6M | 1.5M | 1.6M | −611K | −644K | −591K | −335K | −385K | −382K | −376K | −299K | −217K |
| 負債比 | 19.4% | 19.5% | 25.2% | 135.2% | 137.7% | 135.5% | 119.0% | 122.7% | 122.1% | 122.3% | 117.2% | 111.7% |
| 淨現金(現金 − 有息負債) | – | 325K | 545K | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −200K+304% | – | – | – | −50K | – | – | 57K | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | 18K | 18K | 18K | 18K | 18K | 37K | 18K | 18K | 37K | 74K | 18K | 18K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 2.7M
| Integrated Service Program | 1.1M | 41.7% | +74.3% |
|---|---|---|---|
| Allergy Diagnostic Kit Sales | 823K | 30.6% | -1.2% |
| Immunotherapy Treatment Sales | 488K | 18.1% | +19.2% |
| Clinical Study Revenue | 134K | 5.0% | 0.0% |
| Subscription Revenue | 44K | 1.6% | -19.8% |
| Shipping And Handling | 42K | 1.5% | +16.1% |
| Training And Other Revenue | 41K | 1.5% | +82.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.7M | +26.3% | −457K | -17.0% | 0.02 | – |
| FY2024 | 2.1M | +51.3% | −259K | -12.2% | -0.03 | – |
| FY2023 | 1.4M | +13.3% | −468K | -33.2% | -0.05 | – |
| FY2022 | 1.2M | -12.1% | −996K | -80.1% | -0.11 | – |
| FY2021 | 1.4M | +1035.8% | −770K | -54.5% | -0.10 | – |
| FY2020 | 125K | – | −327K | -262.9% | -0.05 | – |
| FY2019 | – | – | −167K | –% | -0.03 | – |
| FY2018 | – | – | −39K | –% | 0.00 | – |